Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
- Conditions
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 46
- Registration Number
- NCT03988036
- Locations
- 🇩🇪
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg Zentrum für Frauenheilkunde und Abteilung für Senologie, Georgsmarienhütte, Lower Saxony, Germany
🇩🇪Mammazentrum Hamburg, Hamburg, Germany
🇩🇪Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Bavaria, Germany
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 39
- Registration Number
- NCT03820141
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- iOMEDICO AG
- Registration Number
- NCT03811418
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 138
- Registration Number
- NCT03747120
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸New Mexico Cancer Center, Albuquerque, New Mexico, United States
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 454
- Registration Number
- NCT03726879
- Locations
- 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03716180
- Locations
- 🇺🇸
DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Conditions
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 147
- Registration Number
- NCT03644186
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Berard, Lyon, France
🇮🇹Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 650
- Registration Number
- NCT03595592
- Locations
- 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸Hospital Virgen de la Nieves, Granada, Spain
🇮🇹Ospedale Santa Maria della Misericordia, Udine, Italy
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.